John Canan
Fortuna: 5 M $ al 30/06/2026
Fortuna: 5 M $ al 30/06/2026
John Canan worked for Merck & Co., Inc. as Senior VP-Finance & Global Controller from 2014 to 2014.
He also worked for Schering-Plough Corp.
as Chief Accounting Officer, SVP & Global Controller from 2009 to 2009, and for Merck Sharp & Dohme Corp.
as Senior Vice President & Controller from 2009 to 2009.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
Terex Corp.
Terex Corp. Trucks/Construction/Farm MachineryProducer Manufacturing Manufactures and markets aerial work platforms and materials processing machinery 0,06 % | 27/04/2026 | 64.456 ( 0,06 % ) | 5 M $ | 30/06/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| MERCK & CO., INC. | Comptroller/Controller/Auditor | 01/03/2014 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Comptroller/Controller/Auditor | 03/11/2009 |
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Comptroller/Controller/Auditor | 01/11/2009 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Merck & Co., Inc.
Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.